Last week a study showing that immunotherapies may lead to rapid tumor growth in a small subset of patients met with some concern among oncologists and researchers. They worried that the news could dampen enthusiasm surrounding cancer’s most promising new therapy.

Indeed, some of the researchers who observed the effect expressed hesitancy about sharing the news widely.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.